Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | HMGCR | P04035 | 2/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20010940 | 1.00 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL9999399 | 1.00 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL11747448 | 0.93 | HCAR2 (0.43) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL11747435 | 0.93 | HCAR2 (0.43) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL4799720 | 0.85 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL4799716 | 0.85 | HCAR2 (0.46) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL29626440 | 0.85 | HCAR2 (0.55) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL31681514 | 0.85 | HCAR2 (0.55) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL11631787 | 0.83 | MAPT (0.58) | HCAR2MAPTALDH1A1HMGCR | |
| SCHEMBL11631792 | 0.83 | MAPT (0.58) | HCAR2MAPTALDH1A1HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697401-B2 | Method for synthesizing an ω-amino acid or ester from a monounsaturated fatty acid or ester | ARKEMA FRANCE (FR) | 2014-04-15 | — | — | US | disclosed |
| US-20110300590-A1 | Method for Synthesizing an Omega-Amino Acid or Ester from a Monounsaturated Fatty Acid or Ester | ARKEMA FRANCE (FR) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300590-A1 | Method for Synthesizing an Omega-Amino Acid or Ester from a Monounsaturated Fatty Acid or Ester | FASN, ELOVL3, ELOVL5 | HCAR2 313/4885KEAP1 2179/4885NFE2L2 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.